Impact of Saroglitazar on the Metabolic Profile in Type 2 Diabetes Mellitus Patients with Moderate to Severe Hypertriglyceridemia
Shefali Karkhanis, Ami Sanghvi, Manish Shetty, Kunal Jhaveri & Aditi Bhandari · Journal of Advances in Medicine and Medical Research · 2024
Background: Saroglitazar is dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist and approved for elevated triglyceride (TG) reduction in type 2 diabetes mellitus (T2DM) and Non-alcoholic fatty liver disease in India. This study was conducted to evaluate the effect...
Open access
Research Article
10.9734/jammr/2024/v36i95569